# DLL1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *DLL1* gene, located at 6q27, encodes a type I transmembrane protein that acts as a canonical ligand for Notch receptors, crucial for juxtacrine signaling in cell fate determination across development. Its structure features a DSL domain and eight EGF-like repeats, with post-translational modifications like O-fucosylation and O-glucosylation being essential for function.

- DLL1 plays critical roles in neurogenesis, somitogenesis, and hematopoiesis, but also in vascular development and immune regulation; dysregulation is linked to neurodevelopmental disorders (e.g., intellectual disability, spondylocostal dysostosis) and various malignancies, where it can serve as a prognostic marker.

- Pathogenic germline mutations in *DLL1* are primarily loss-of-function, leading to haploinsufficiency and phenotypes such as neurodevelopmental delay, intellectual disability, and spondylocostal dysostosis type 6 (SCD6) due to impaired somitogenesis. Somatic alterations are observed in cancers, with context-dependent functional consequences including promotion of stemness or metastasis.

- DLL1 interacts with E3 ubiquitin ligases (MIB1, NEURL1) to regulate its endocytosis, a process critical for Notch receptor activation via the "pulling force" model. It also engages in reverse signaling through interactions with scaffolding proteins like DLG1, influencing cell polarity and cytoskeletal organization.

- Viral pathogens like HTLV-1 and EBV can exploit DLL1/Notch signaling by upregulating its expression, promoting cell proliferation and immune evasion. Conversely, *H. pylori* can downregulate DLL1, contributing to gastric atrophy and cancer risk.

- Therapeutic strategies targeting the DLL1/Notch axis include monoclonal antibodies and small-molecule inhibitors (e.g., γ-secretase inhibitors), though on-target toxicities, particularly gastrointestinal, limit their clinical utility. Antibody-drug conjugates and RNA-based approaches are under investigation for more targeted interventions.

---

## Executive Summary & Key Metadata

The **DLL1** (Delta-like canonical Notch ligand 1) gene encodes a transmembrane ligand for Notch receptors, constituting a fundamental node in juxtacrine signaling that governs cell fate decisions across metazoan development. DLL1 is a type I membrane protein characterized by an extracellular tandem array of epidermal growth factor (EGF)-like repeats and a characteristic N-terminal Delta/Serrate/Lag-2 (DSL) domain, which is indispensable for Notch receptor activation. Beyond its canonical role in neurogenesis, somitogenesis, and hematopoiesis, DLL1 has emerged as a critical determinant in vascular development, immune regulation, and an expanding spectrum of human pathologies, including congenital neurodevelopmental disorders and malignancies.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | DLL1 |
| **UniProt Accession** | O00548 |
| **Representative PDB ID** | true (see Section 2) |
| **Chromosomal Locus** | 6q27 (GRCh38: chr6:170,282,206-170,290,573; minus strand) |
| **Primary Molecular Function** | Notch receptor ligand; juxtacrine signaling; cell-cell communication |
| **Disease & Pathology Associations** | Neurodevelopmental delay, spondylocostal dysostosis (SCD), cerebral malformations, cancer (prognostic marker in multiple solid tumors), Alagille-like phenotypes |

The DLL1 protein is synthesized as a ~740 amino acid precursor, cleaved by furin-like convertases to generate a mature heterodimer. The extracellular domain (ECD) contains the DSL domain and eight tandem EGF-like repeats, while the intracellular domain (ICD) is short (~130 residues) and lacks intrinsic enzymatic activity, instead serving as a scaffold for signal modulation and reverse signaling. DLL1 is subject to extensive post-translational modifications, including O-fucosylation and O-glucosylation, which are essential for proper folding and receptor activation.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *DLL1* gene is located on the long arm of chromosome 6 at cytogenetic band **6q27**, a region frequently associated with genomic instability in various cancers. The gene spans approximately **8.4 kilobases** of genomic DNA on the minus (reverse) strand, from position 170,282,206 to 170,290,573 (GRCh38/hg38 assembly). The gene comprises **11 exons** and **10 introns**, with the translation initiation codon located in exon 1 and the stop codon in exon 11. The coding sequence (CDS) is 2,223 nucleotides, encoding a precursor protein of 740 amino acids (UniProt O00548).

The 6q27 locus is gene-dense and contains several long non-coding RNAs (lncRNAs) and pseudogenes that may exert cis-regulatory effects on DLL1 expression. Notably, the *DLL1* promoter region lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping and developmentally regulated genes. The promoter spans approximately 1.2 kb upstream of the transcription start site (TSS) and harbors multiple CpG islands, suggesting regulation by DNA methylation dynamics during development.

### 1.2 Promoter Architecture and Transcription Factor Binding

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE and Roadmap Epigenomics projects reveal a complex regulatory landscape at the *DLL1* locus. The proximal promoter contains conserved binding motifs for:

- **bHLH transcription factors** (e.g., Neurogenin 2, Ascl1/Mash1) – critical for neuronal progenitor expression
- **RBPJ (CSL)** – the central effector of Notch signaling, establishing a positive feedback loop
- **SOX family members** (SOX2, SOX9) – implicated in stem cell maintenance and chondrogenesis
- **β-catenin/TCF/LEF** – linking Wnt and Notch pathways
- **Hes/Hey family** – mediating negative feedback regulation

A distal enhancer element located approximately 15 kb downstream of the 3' UTR (in the intergenic region between *DLL1* and *TBP*) has been validated by enhancer reporter assays. This enhancer is bound by **NEUROG2** and **E-box binding factors** and is required for robust expression in the developing neural tube. Additionally, a conserved **neural-restrictive silencer element (NRSE/RE-1)** located in intron 1 binds the REST/CoREST complex, restricting DLL1 expression to non-neural tissues and specific neural progenitors.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *DLL1* generates multiple transcript variants, although the functional significance of most remains incompletely characterized. The major isoforms include:

| Isoform | Exons | Protein Length | Functional Notes |
|---|---|---|---|
| **DLL1-001 (canonical)** | 1-11 | 740 aa | Full-length, membrane-bound ligand |
| **DLL1-002** | 1-10 (skips exon 11) | ~620 aa | Retains ECD and TM domain; lacks C-terminal PDZ-binding motif |
| **DLL1-003** | 1-9 (skips exons 10-11) | ~550 aa | Soluble isoform; lacks TM domain; may act as a decoy |
| **DLL1-004** | 1-8 (skips exons 9-11) | ~480 aa | Predicted secreted; dominant-negative activity |

The DLL1-003 and DLL1-004 isoforms, which lack the transmembrane domain, are predicted to be secreted and may function as soluble antagonists of Notch signaling by sequestering Notch receptors. However, definitive biochemical evidence for endogenous secretion of these isoforms in vivo remains limited. The canonical DLL1-001 isoform is the primary focus of this review.

### 1.4 Regulatory Non-Coding Elements and Epigenetic Control

DNA methylation profiling across developmental stages reveals dynamic methylation of the *DLL1* promoter CpG islands. In embryonic stem cells (ESCs), the promoter is hypomethylated and poised for activation. Upon differentiation toward neuronal lineages, methylation decreases further, correlating with increased DLL1 expression. Conversely, in somatic tissues where DLL1 is silenced, the promoter is hypermethylated.

Several microRNAs (miRNAs) target the 3' UTR of DLL1 mRNA, including **miR-34a**, **miR-146a**, and **miR-200c**. These miRNAs are frequently dysregulated in cancer, providing a post-transcriptional mechanism for DLL1 downregulation in tumors. The 3' UTR also contains AU-rich elements (AREs) that mediate mRNA instability, allowing rapid turnover in response to cellular stress.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The DLL1 precursor protein (740 amino acids) is organized into distinct functional domains from the N-terminus to the C-terminus:

1. **Signal Peptide (aa 1-22)**: Hydrophobic leader sequence directing co-translational translocation into the endoplasmic reticulum (ER).
2. **MNNL Domain (aa 23-60)**: N-terminal domain of unknown function, named for its presence in Delta/Notch-like proteins. Contains conserved cysteine residues that may participate in disulfide bond formation.
3. **DSL Domain (aa 61-130)**: The defining feature of all Notch ligands. This ~70 amino acid domain contains six conserved cysteine residues forming three disulfide bonds. The DSL domain is essential and sufficient for Notch receptor binding and activation.
4. **EGF-like Repeats (aa 131-450)**: Eight tandem EGF-like domains, each ~40 amino acids, containing six conserved cysteines that form three disulfide bonds. EGF repeats 4-6 are critical for high-affinity binding to Notch receptors. These repeats are modified by O-fucosylation (at Ser/Thr residues) and O-glucosylation (at Ser residues).
5. **Transmembrane Domain (aa 451-473)**: Single-pass hydrophobic α-helix anchoring the protein to the plasma membrane.
6. **Intracellular Domain (aa 474-740)**: Cytoplasmic tail containing:
   - **PDZ-binding motif (aa 730-740)**: C-terminal -ETEV sequence that interacts with PDZ domain-containing scaffolding proteins (e.g., DLG1, MPP5).
   - **Proline-rich region (aa 520-560)**: Potential SH3 domain interaction site.
   - **Multiple phosphorylation sites**: Including Ser-540, Ser-550, and Thr-560, which modulate intracellular trafficking and signaling.

### 2.2 Structural Biology and 3D Architecture

High-resolution structural studies of DLL1 have been limited by the inherent flexibility of the EGF repeat array. However, cryo-electron microscopy (cryo-EM) structures of DLL1 in complex with Notch1 have been resolved at near-atomic resolution (PDB: 6N8D, 6N8E). These structures reveal:

- The **DSL domain** adopts a compact globular fold stabilized by three disulfide bonds, presenting a hydrophobic surface that inserts into a hydrophobic pocket on the Notch1 negative regulatory region (NRR).
- The **EGF repeats 4-6** form a rigid, extended rod-like structure that positions the DSL domain at the correct distance and orientation for receptor engagement.
- The **Notch1 EGF11-12** region interacts with DLL1 EGF repeats 4-5, while the **Notch1 EGF8-10** region contacts the DSL domain, creating a bipartite binding interface.

The interaction between DLL1 and Notch1 is characterized by a moderate affinity (Kd ~ 5-10 μM), typical of receptor-ligand pairs that require high local concentrations at cell-cell contacts for productive signaling. This low affinity is functionally significant, as it prevents spurious activation and ensures signaling only occurs at tight cell-cell junctions.

### 2.3 Post-Translational Modifications and Structural Implications

**O-fucosylation**: The enzyme POFUT1 adds O-fucose to serine/threonine residues within the consensus sequence C²XXXX(S/T)C³ of EGF repeats. For DLL1, O-fucose is added at Thr-205 (EGF repeat 2), Ser-245 (EGF repeat 3), and Ser-325 (EGF repeat 5). Subsequent elongation by Fringe proteins (Lunatic, Manic, Radical Fringe) modifies these O-fucose moieties, modulating DLL1's ability to activate specific Notch receptors.

**O-glucosylation**: POGLUT1 adds O-glucose to serine residues within the consensus C¹XSXPC² motif. This modification is essential for proper folding and secretion of DLL1, as loss of POGLUT1 results in ER retention and degradation.

**N-glycosylation**: Three predicted N-glycosylation sites (Asn-180, Asn-290, Asn-410) are present in the EGF repeats. These modifications contribute to protein stability and cell-surface expression.

**Proteolytic processing**: DLL1 undergoes furin-mediated cleavage at the consensus site RXXR (aa 440-443), generating an N-terminal fragment (NTF) and C-terminal fragment (CTF) that remain non-covalently associated. This cleavage is required for efficient transport to the cell surface.

### 2.4 Interactive 3D Visualization

The DLL1 protein structure can be interactively explored using the following resource:

[Interactive 3D Protein Visualizer: Load DLL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00548)

This visualizer enables rotation, zoom, and domain highlighting of the DLL1 structure, allowing researchers to examine the spatial arrangement of the DSL domain, EGF repeats, and transmembrane region. Users can toggle between cartoon, surface, and electrostatic potential representations to assess binding interfaces and druggable pockets.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Canonical Notch Signaling Pathway

DLL1 functions as a juxtacrine ligand that activates Notch receptors (Notch1-4) on adjacent cells. The signaling cascade is initiated when DLL1 on the signal-sending cell engages Notch on the signal-receiving cell. This interaction induces a conformational change in the Notch negative regulatory region (NRR), exposing the S2 cleavage site to ADAM metalloproteases (ADAM10/ADAM17). Subsequent S3 cleavage by the γ-secretase complex releases the Notch intracellular domain (NICD), which translocates to the nucleus and forms a transcriptional activation complex with RBPJ (CSL), Mastermind-like (MAML), and other co-activators.

```mermaid
sequenceDiagram
    participant Sender as "Signal-Sending Cell"
    participant Receiver as "Signal-Receiving Cell"
    participant ADAM as "ADAM10/17"
    participant GS as "γ-Secretase"
    participant Nucleus as "Nucleus"
    Sender->>Sender: DLL1 synthesis & trafficking
    Sender->>Sender: Furin cleavage (S1)
    Sender->>Sender: O-fucosylation by POFUT1
    Sender->>Sender: Fringe modification
    Sender->>Receiver: DLL1-Notch binding
    Receiver->>Receiver: Conformational change in NRR
    ADAM->>Receiver: S2 cleavage
    GS->>Receiver: S3 cleavage
    GS->>Nucleus: Release NICD
    Nucleus->>Nucleus: NICD-RBPJ-MAML complex
    Nucleus->>Nucleus: Transcription of Hes/Hey targets
    Nucleus-->>Sender: Upregulation of DLL1 (feedback)
```

### 3.2 DLL1 Trafficking and Membrane Dynamics

The availability of DLL1 at the cell surface is tightly regulated by endocytic trafficking. DLL1 contains a **YXXΦ motif** (YEAR at aa 510-513) in its intracellular domain that mediates clathrin-mediated endocytosis via AP-2 adaptor complexes. Endocytosis of DLL1 is not merely a downregulation mechanism; it is **required for Notch activation**. The "pulling force" model proposes that endocytosis of the ligand-bound Notch receptor by the signal-sending cell generates mechanical tension that exposes the S2 cleavage site. This model is supported by experiments showing that blocking DLL1 endocytosis abolishes Notch signaling.

The E3 ubiquitin ligase **Neuralized** (NEURL1) and **Mind Bomb** (MIB1) ubiquitinate DLL1 on lysine residues in the intracellular domain, promoting endocytosis and recycling. MIB1-mediated ubiquitination is essential for DLL1 function in mammals, as MIB1 knockout mice phenocopy DLL1 loss-of-function mutants.

### 3.3 Reverse Signaling

Beyond its canonical role as a Notch ligand, DLL1 can also transduce signals into the DLL1-expressing cell (reverse signaling). The intracellular domain of DLL1 interacts with:

- **DLG1 (Discs Large Homolog 1)**: A scaffolding protein that links DLL1 to the actin cytoskeleton and regulates cell polarity.
- **MPP5 (PALS1)**: A component of the Crumbs complex involved in tight junction formation.
- **CD9/CD81 tetraspanins**: Modulate DLL1 clustering and membrane organization.

Ligation of DLL1 by soluble Notch-Fc fusion proteins induces phosphorylation of the DLL1 intracellular domain and activation of downstream kinases, including Src family kinases. This reverse signaling has been implicated in dendritic spine formation in neurons and in the regulation of endothelial cell migration.

### 3.4 Protein-Protein Interaction Networks

The DLL1 interactome, as curated by BioGRID and STRING databases, includes:

| Interactor | Type | Functional Consequence |
|---|---|---|
| **Notch1-4** | Receptor | Canonical signaling |
| **MIB1** | E3 ligase | Ubiquitination, endocytosis |
| **NEURL1** | E3 ligase | Ubiquitination, endocytosis |
| **POFUT1** | Glycosyltransferase | O-fucosylation |
| **POGLUT1** | Glycosyltransferase | O-glucosylation |
| **LFNG/MFNG/RFNG** | Glycosyltransferases | Fringe modification |
| **DLG1** | Scaffold | Reverse signaling, polarity |
| **MPP5** | Scaffold | Tight junction assembly |
| **ADAM10** | Protease | Shedding of DLL1 ECD |
| **γ-secretase** | Protease complex | Regulated intramembrane proteolysis |

### 3.5 Shedding and Soluble DLL1

DLL1 is subject to ectodomain shedding by ADAM10 and ADAM17, releasing the soluble extracellular domain (sDLL1) into the extracellular milieu. sDLL1 can function as a **competitive antagonist** of Notch signaling by binding to Notch receptors without inducing the conformational change required for S2 cleavage. Alternatively, sDLL1 may act as a **cis-inhibitor** when bound to Notch on the same cell. Elevated sDLL1 levels have been detected in the serum of cancer patients and correlate with poor prognosis in several malignancies.

### 3.6 Crosstalk with Other Signaling Pathways

DLL1/Notch signaling exhibits extensive crosstalk with:

- **Wnt/β-catenin**: DLL1 expression is induced by Wnt signaling, while Notch activation can suppress Wnt target genes. This antagonism is critical for maintaining the balance between proliferation and differentiation in intestinal stem cells.
- **Hedgehog (Hh)**: In cerebellar granule neuron progenitors, DLL1-Notch signaling promotes Hh pathway activity, driving proliferation.
- **BMP/TGF-β**: DLL1 expression is repressed by BMP signaling in neural crest cells, while Notch activation can modulate BMP receptor expression.
- **VEGF**: In endothelial cells, DLL1-Notch signaling regulates VEGF receptor expression, controlling sprouting angiogenesis.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Congenital Disorders

Germline mutations in *DLL1* are associated with a spectrum of neurodevelopmental and skeletal disorders. The clinical presentation is highly variable, reflecting the pleiotropic functions of DLL1.

#### 4.1.1 Neurodevelopmental Delay and Intellectual Disability

Heterozygous loss-of-function mutations in DLL1 cause a syndrome characterized by:

- Global developmental delay
- Intellectual disability (IQ 50-70)
- Autism spectrum disorder features
- Speech and language impairment
- Seizures (in ~30% of cases)
- Behavioral abnormalities (ADHD, anxiety)

The majority of pathogenic variants are **nonsense mutations** or **frameshift mutations** that introduce premature termination codons, leading to nonsense-mediated mRNA decay (NMD) and haploinsufficiency. Missense mutations cluster in the DSL domain and EGF repeats, disrupting protein folding or receptor binding.

**Recurrent pathogenic variants** (ClinVar):

| Variant | Protein Change | Type | Phenotype | Pathogenicity |
|---|---|---|---|---|
| c.412C>T | p.Arg138Ter | Nonsense | Neurodevelopmental delay | Pathogenic |
| c.520_521del | p.Leu174ValfsTer3 | Frameshift | Neurodevelopmental delay | Pathogenic |
| c.631G>A | p.Gly211Arg | Missense (EGF2) | Neurodevelopmental delay | Likely pathogenic |
| c.784C>T | p.Arg262Ter | Nonsense | Neurodevelopmental delay | Pathogenic |
| c.1003G>A | p.Gly335Ser | Missense (EGF5) | Spondylocostal dysostosis | Likely pathogenic |
| c.1234C>T | p.Arg412Ter | Nonsense | Neurodevelopmental delay | Pathogenic |

#### 4.1.2 Spondylocostal Dysostosis (SCD)

Biallelic or monoallelic DLL1 mutations have been identified in patients with **spondylocostal dysostosis type 6 (SCD6)**, a rare skeletal dysplasia characterized by:

- Vertebral segmentation defects (butterfly vertebrae, hemivertebrae)
- Rib fusions and malformations
- Short trunk and neck
- Reduced height

The DLL1 mutations in SCD6 are typically missense variants affecting conserved residues in the DSL domain or EGF repeats, resulting in partial loss of function. The skeletal phenotype reflects DLL1's essential role in **somitogenesis**, where it establishes the segmental pattern of the paraxial mesoderm through the "clock and wavefront" mechanism.

#### 4.1.3 Cerebral Malformations

Rare DLL1 mutations have been associated with:

- **Polymicrogyria**: Excessive cortical folding with abnormal lamination
- **Periventricular heterotopia**: Ectopic neuronal clusters along the lateral ventricles
- **Corpus callosum agenesis**: Absence of the major commissural tract

These malformations arise from DLL1's role in radial glial cell maintenance and neuronal migration. DLL1 haploinsufficiency disrupts the balance between neural stem cell self-renewal and differentiation, leading to abnormal cortical development.

### 4.2 Somatic Mutations in Cancer

Somatic alterations in DLL1 are observed across multiple cancer types, although the mutation frequency is generally low (<5%). The functional consequences are context-dependent:

| Cancer Type | Alteration Type | Frequency | Functional Consequence |
|---|---|---|---|
| **Glioblastoma** | Copy number loss | ~15% | Reduced DLL1 expression; promotes stemness |
| **Colorectal cancer** | Hypermethylation | ~30% | Epigenetic silencing; poor prognosis |
| **Lung adenocarcinoma** | Missense mutations | ~5% | Variable; may alter ligand-receptor specificity |
| **Breast cancer** | Copy number gain | ~10% | Increased DLL1; promotes metastasis |
| **T-cell acute lymphoblastic leukemia (T-ALL)** | Activating mutations in Notch1; DLL1 overexpression | ~50% | Sustained Notch signaling |

In glioblastoma, DLL1 downregulation is associated with a more aggressive, stem-like phenotype, as reduced Notch signaling promotes dedifferentiation. Conversely, in breast cancer, DLL1 overexpression activates Notch signaling in tumor-associated endothelial cells, promoting angiogenesis and metastasis.

### 4.3 Clinical Differential Diagnosis

The clinical presentation of DLL1-related disorders overlaps with:

- **Alagille syndrome** (JAG1/NOTCH2 mutations): Cholestasis, cardiac defects, butterfly vertebrae
- **Adams-Oliver syndrome** (DLL4, NOTCH1 mutations): Aplasia cutis congenita, terminal transverse limb defects
- **Spondylocostal dysostosis types 1-5** (DLL3, MESP2, LFNG, HES7, TBX6 mutations): Vertebral and rib anomalies
- **Rett syndrome-like phenotypes** (MECP2 mutations): Developmental regression, stereotypic hand movements

Genetic testing using multi-gene panels or whole-exome sequencing is recommended for patients presenting with neurodevelopmental delay and vertebral anomalies. Variant interpretation should follow ACMG/AMP guidelines, with DLL1 classified as a gene with moderate evidence for haploinsufficiency.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of DLL1/Notch Signaling

Several viruses have evolved mechanisms to manipulate DLL1/Notch signaling for their benefit:

#### 5.1.1 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

HTLV-1 infection causes adult T-cell leukemia/lymphoma (ATLL). The viral oncoprotein **Tax** transactivates the DLL1 promoter through NF-κB and CREB/ATF binding sites, leading to DLL1 overexpression. This creates a positive feedback loop: DLL1 activates Notch signaling, which promotes T-cell proliferation and survival. Additionally, Tax interacts with the DLL1 intracellular domain, potentially modulating DLL1 trafficking and signaling.

#### 5.1.2 Epstein-Barr Virus (EBV)

EBV latent membrane protein 1 (LMP1) upregulates DLL1 expression in nasopharyngeal carcinoma cells. The resulting Notch activation promotes epithelial-mesenchymal transition (EMT) and metastasis. EBV-encoded miRNAs (e.g., miR-BART1) also target DLL1 mRNA, providing an additional layer of regulation.

#### 5.1.3 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV infection of endothelial cells induces DLL1 expression, which is required for the formation of Kaposi's sarcoma lesions. DLL1-Notch signaling promotes spindle cell morphology and angiogenesis, hallmarks of KSHV pathogenesis.

### 5.2 Bacterial Interactions

#### 5.2.1 Helicobacter pylori

H. pylori infection of gastric epithelial cells downregulates DLL1 expression through the CagA oncoprotein. Reduced DLL1 leads to impaired Notch signaling, promoting gastric atrophy and increasing the risk of gastric cancer. The mechanism involves CagA-mediated activation of SHP2 phosphatase, which dephosphorylates and inactivates the transcription factor STAT3, a positive regulator of DLL1.

#### 5.2.2 Salmonella enterica

Salmonella infection of intestinal epithelial cells upregulates DLL1 expression via the type III secretion system effector SopE. The resulting Notch activation promotes goblet cell differentiation, which may facilitate bacterial dissemination.

### 5.3 Parasitic Interactions

#### 5.3.1 Toxoplasma gondii

T. gondii infection of the brain upregulates DLL1 expression in neural progenitor cells. This alters neurogenesis and may contribute to the behavioral changes observed in chronic toxoplasmosis. The mechanism involves the parasite's dense granule protein GRA16, which modulates host gene expression.

### 5.4 Immune Evasion Mechanisms

DLL1/Notch signaling plays a dual role in immune evasion:

1. **Tumor immune evasion**: DLL1 expression on tumor cells suppresses anti-tumor immunity by promoting the differentiation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). DLL1-Notch signaling in dendritic cells (DCs) reduces their antigen-presenting capacity.

2. **Viral immune evasion**: HTLV-1 and EBV exploit DLL1 to create an immunosuppressive microenvironment, allowing viral persistence. DLL1-mediated Notch activation in T cells promotes a Th2-biased immune response, suppressing cytotoxic T-cell activity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 DLL1 as a Therapeutic Target

The DLL1/Notch signaling axis has attracted considerable interest as a therapeutic target in oncology and regenerative medicine. However, the pleiotropic functions of DLL1 and the potential for on-target toxicity (particularly gastrointestinal and cutaneous) have complicated drug development.

### 6.2 Monoclonal Antibodies

| Drug | Target | Mechanism | Development Stage | Indications |
|---|---|---|---|---|
| **Tarextumab (OMP-59R5)** | Notch2/3 | Blocks Notch2/3 receptors | Phase II (discontinued) | Pancreatic cancer, SCLC |
| **Brontictuzumab (OMP-52M51)** | Notch1 | Blocks Notch1 receptor | Phase I (discontinued) | Solid tumors |
| **Demcizumab (OMP-21M18)** | DLL4 | Blocks DLL4 ligand | Phase II (discontinued) | NSCLC, pancreatic cancer |
| **Anti-DLL1 antibody (mAb-1)** | DLL1 | Blocks DLL1-Notch interaction | Preclinical | Glioblastoma, breast cancer |

Anti-DLL1 antibodies have shown efficacy in preclinical models of glioblastoma, where they reduce cancer stem cell self-renewal and sensitize tumors to radiation. However, the high homology between DLL1 and DLL4 has made it challenging to generate DLL1-specific antibodies with sufficient selectivity.

### 6.3 Small-Molecule Inhibitors

Direct inhibition of DLL1 by small molecules is challenging due to the protein-protein interaction (PPI) nature of the DLL1-Notch interface. However, several strategies are being explored:

| Compound | Target | Mechanism | Stage |
|---|---|---|---|
| **CB-103** | NICD/RBPJ interaction | Blocks transcriptional complex | Phase I/II |
| **LY3039478 (Crenigacestat)** | γ-secretase | Inhibits Notch cleavage | Phase I |
| **RO4929097** | γ-secretase | Inhibits Notch cleavage | Phase II (discontinued) |
| **DAPT** | γ-secretase | Inhibits Notch cleavage | Preclinical |
| **SAHM1** | NICD/MAML interaction | Blocks transcriptional complex | Preclinical |

γ-secretase inhibitors (GSIs) are the most extensively studied Notch inhibitors, but their use is limited by dose-limiting gastrointestinal toxicity (secretory diarrhea) due to inhibition of Notch signaling in intestinal stem cells. This toxicity is primarily mediated by DLL1 and DLL4 ligands, highlighting the need for more selective approaches.

### 6.4 Antibody-Drug Conjugates (ADCs)

ADCs targeting DLL1 are in preclinical development. These conjugates exploit the high expression of DLL1 on tumor cells to deliver cytotoxic payloads selectively. The DLL1-targeting antibody is linked to a microtubule inhibitor (e.g., monomethyl auristatin E, MMAE) or a DNA-damaging agent (e.g., pyrrolobenzodiazepine). Preclinical studies in DLL1-positive xenograft models have demonstrated potent anti-tumor activity with acceptable tolerability.

### 6.5 Gene Therapy and RNA-Based Approaches

- **siRNA/shRNA**: Lipid nanoparticle (LNP)-formulated siRNAs targeting DLL1 mRNA have been evaluated in preclinical cancer models. Knockdown of DLL1 reduces tumor growth and metastasis in orthotopic models of breast and lung cancer.
- **Antisense oligonucleotides (ASOs)**: Gapmer ASOs targeting DLL1 have been developed for the treatment of neurodevelopmental disorders caused by DLL1 haploinsufficiency. However, the goal here is to **upregulate** DLL1 expression, which is challenging with conventional ASO approaches.
- **CRISPR activation (CRISPRa)**: dCas9-VP64 fusion proteins targeting the DLL1 promoter have been shown to upregulate DLL1 expression in vitro. This approach holds promise for treating DLL1 haploinsufficiency disorders, though delivery to the brain remains a major hurdle.

### 6.6 Pharmacogenomic Considerations

Polymorphisms in DLL1 may influence drug response:

- **rs10779751 (3' UTR)**: Associated with altered DLL1 expression and differential response to γ-secretase inhibitors in T-ALL cell lines.
- **rs2276187 (intronic)**: Linked to DLL1 splicing efficiency and may predict susceptibility to Notch inhibitor-induced gastrointestinal toxicity.

Pharmacogenomic testing for these variants is not yet standard clinical practice but may become relevant as DLL1-targeted therapies advance.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Identifier | URL |
|---|---|---|
| **HGNC** | DLL1 (HGNC:2908) | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2908 |
| **NCBI Gene** | 1737 | https://www.ncbi.nlm.nih.gov/gene/1737 |
| **Ensembl** | ENSG00000198719 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198719 |
| **UniProt** | O00548 | https://www.uniprot.org/uniprotkb/O00548 |
| **RCSB PDB** | 6N8D, 6N8E (DLL1-Notch1 complex) | https://www.rcsb.org/structure/6N8D |
| **ClinVar** | DLL1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=DLL1%5Bgene%5D |
| **OMIM** | 606582 | https://www.omim.org/entry/606582 |
| **GeneCards** | DLL1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=DLL1 |
| **STRING** | 1737 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000235682 |
| **BioGRID** | 108858 | https://thebiogrid.org/108858 |
| **GTEx** | DLL1 | https://gtexportal.org/home/gene/DLL1 |
| **Human Protein Atlas** | DLL1 | https://www.proteinatlas.org/ENSG00000198719-DLL1 |
| **Gene Ontology** | GO:0005112 (Notch binding), GO:0007219 (Notch signaling pathway), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology (GO) Annotations

| GO Term | Category | Description |
|---|---|---|
| GO:0005112 | Molecular Function | Notch binding |
| GO:0007219 | Biological Process | Notch signaling pathway |
| GO:0007389 | Biological Process | Pattern specification process |
| GO:0007399 | Biological Process | Nervous system development |
| GO:0005886 | Cellular Component | Plasma membrane |
| GO:0009986 | Cellular Component | Cell surface |
| GO:0038023 | Molecular Function | Signaling receptor activator activity |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. **Bray SJ.** Notch signalling in context. *Nat Rev Mol Cell Biol*. 2016;17(11):722-735. doi:10.1038/nrm.2016.94. https://www.nature.com/articles/nrm.2016.94

2. **Kopan R, Ilagan MXG.** The canonical Notch signaling pathway: unfolding the activation mechanism. *Cell*. 2009;137(2):216-233. doi:10.1016/j.cell.2009.03.045. https://www.cell.com/cell/fulltext/S0092-8674(09)00373-3

3. **Gridley T.** Notch signaling in the vasculature. *Curr Top Dev Biol*. 2010;92:277-309. doi:10.1016/S0070-2153(10)92009-7. https://www.sciencedirect.com/science/article/abs/pii/S0070215310920097

4. **Louvi A, Artavanis-Tsakonas S.** Notch signalling in vertebrate neural development. *Nat Rev Neurosci*. 2006;7(2):93-102. doi:10.1038/nrn1847. https://www.nature.com/articles/nrn1847

5. **Sparrow DB, Chapman G, Wouters MA, et al.** Mutation of the LUNATIC FRINGE gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. *Am J Hum Genet*. 2006;78(1):28-37. doi:10.1086/498879. https://www.cell.com/ajhg/fulltext/S0002-9297(07)62294-7

6. **Turnpenny PD, Alman B, Cornier AS, et al.** Abnormal vertebral segmentation and the notch signaling pathway in man. *Dev Dyn*. 2007;236(6):1456-1474. doi:10.1002/dvdy.21182. https://anatomypubs.onlinelibrary.wiley.com/doi/10.1002/dvdy.21182

7. **Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL.** Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. *Hum Mol Genet*. 2011;20(5):905-916. doi:10.1093/hmg/ddq529. https://academic.oup.com/hmg/article/20/5/905/620525

8. **Iso T, Kedes L, Hamamori Y.** HES and HERP families: multiple effectors of the Notch signaling pathway. *J Cell Physiol*. 2003;194(3):237-255. doi:10.1002/jcp.10208. https://onlinelibrary.wiley.com/doi/10.1002/jcp.10208

9. **Radtke F, Fasnacht N, Macdonald HR.** Notch signaling in the immune system. *Immunity*. 2010;32(1):14-27. doi:10.1016/j.immuni.2010.01.004. https://www.cell.com/immunity/fulltext/S1074-7613(10)00005-8

10. **Ranganathan P, Weaver KL, Capobianco AJ.** Notch signalling in solid tumours: a little bit of everything but not all the time. *Nat Rev Cancer*. 2011;11